View Older Stories View More Recent Stories
-
Citius Pharmaceuticals (CTXR) Receives FDA Approval for LYMPHIR (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
-
Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
-
Citius Pharmaceuticals (CTXR) Announces TenX Keane Shareholder Approval of Merger with Citius Oncology
-
TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals
-
Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.
-
Biopharma Stocks Transformative Innovation for the Future of Health
-
Citius Pharmaceuticals (CTXR) Details Near-Term Milestones for Late-Stage Candidates
-
Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates
-
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
-
Citius Pharmaceuticals (CTXR) Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
-
Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
-
Citius Pharmaceuticals (CTXR) Halted, News Pending
-
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update
-
Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences
-
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering
-
Citius Pharmaceuticals (CTXR) Announces $15 Million Registered Direct Offering
-
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
-
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
-
Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
-
Citius Pharmaceuticals (CTXR) Announces FDA Acceptance of BLA Resubmission of LYMPHIR for Treatment of Adults with R/R Cutaneous T-Cell Lymphoma
-
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
-
Citius Pharmaceuticals (CTXR) Granted Nasdaq Hearing
-
Citius Pharmaceuticals (CTXR) Wins $2.4M via NJ Economic Development Program
-
Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program
-
Citius Pharmaceuticals (CTXR) Files S-3 Shelf to Replace Prior Shelf Registration
-
Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration
-
Citius Pharmaceuticals (CTXR) Files $250M Mixed Shelf
-
Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences
-
Citius Pharmaceuticals, Inc. (CTXR) Reports Q1 Loss of $0.06
-
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
-
Citius Pharmaceuticals (CTXR) Resubmits the BLA for LYMPHIR
-
Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
-
Citius Pharmaceuticals (CTXR) Appoints Robert J. Smith to its Board
-
Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors
-
Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters
-
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update
-
Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023
-
Citius Pharmaceuticals (CTXR) Announces Publication of Positive Results from Solid Tumor Study of LYMPHIR in Combination with Checkpoint Inhibitor
-
Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor
-
Citius Pharmaceuticals (CTXR) to Merge Wholly Owned Subsidiary with TenX Keane Acquisition (TENK) to Form Publicly Listed Citius Oncology, Inc.
-
Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.
-
Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023
-
Citius Pharmaceuticals (CTXR) Announces Passing of Board Member Howard Safir
-
Citius Pharmaceuticals Mourns the Loss of Board Member, Howard Safir
-
Citius Pharmaceuticals (CTXR) Receives Regulatory Guidance from the FDA for the Planned Resubmission of the BLA for LYMPHIR
-
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR™
-
Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023
-
Citius Pharmaceuticals, Inc. (CTXR) Reports In-Line Q3 EPS
-
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update
-
Citius Pharmaceuticals (CTXR) Reaches 92 Event Milestone in Mino-Lok Phase 3 Trial
